Holoprosencephaly (HPE), which results from failed or incomplete midline forebrain division early in gestation, is the most common forebrain malformation. The etiology of HPE is complex and multifactorial. To date, at least 12 HPE-associated genes have been identified, including TGIF (transforming growth factor beta-induced factor), located on chromosome 18p11.3. TGIF encodes a transcriptional repressor of retinoid responses involved in TGF-β signaling regulation, including Nodal signaling. TGIF mutations are reported in approximately 1–2% of patients with non-syndromic, non-chromosomal HPE.We combined data from our comprehensive studies of HPE with a literature search for all individuals with HPE and evidence of mutations affecting TGIF in order to establish the genotypic and phenotypic range. We describe 2 groups of patients: 34 with intragenic mutations and 21 with deletions of TGIF. These individuals, which were ascertained from our research group, in collaboration with other centers, and through a literature search, include 38 probands and 17 mutation-positive relatives. The majority of intragenic mutations occur in the TGIF homeodomain. Patients with mutations affecting TGIF recapitulate the entire phenotypic spectrum observed in non-chromosomal, non-syndromic HPE. We identified a statistically significant difference between the 2 groups with respect to inheritance, as TGIF deletions were more likely to be de novo in comparison to TGIF mutations (χ2(2) = 6.97, ppermutated = 0.0356). In addition, patients with TGIF deletions were also found to more commonly present with manifestations beyond the craniofacial and neuroanatomical features associated with HPE (p = 0.0030). These findings highlight differences in patients with intragenic mutations versus deletions affecting TGIF, and draw attention to the homeodomain region, which appears to be particularly relevant to HPE. These results may be useful for genetic counseling of affected patients.

Keywords:
Holoprosencephaly, Monosomy 18p, 18p, 18p deletion, TGIF
1.
Aguilella C, Dubourg C, Attia-Sobol J, Vigneron J, Blayau M, et al: Molecular screening of the TGIF gene in holoprosencephaly: identification of two novel mutations. Hum Genet 112:131–134 (2003).
2.
Aughton DJ, AlSaadi AA, Transue DJ: Single maxillary central incisor in a girl with del(18p) syndrome. J Med Genet 28:530–532 (1991).
3.
Barkovich AJ, Quint DJ: Middle interhemispheric fusion: an unusual variant of holoprosencephaly. AJNR Am J Neuroradiol 14:431–440 (1993).
4.
Bartholin L, Powers SE, Melhuish TA, Lasse S, Weinstein M, Wotton D: TGIF inhibits retinoid signaling. Mol Cell Biol 26:990–1001 (2006).
5.
Bendavid C, Haddad BR, Griffin A, Huizing M, Dubourg C, et al: Multicolour FISH and quantitative PCR can detect submicroscopic deletions in holoprosencephaly patients with a normal karyotype. J Med Genet 43:496–500 (2006).
6.
Bendavid C, Rochard L, Dubourg C, Seguin J, Gicquel I, et al: Array-CGH analysis indicates a high prevalence of genomic rearrangements in holoprosencephaly: an updated map of candidate loci. Hum Mutat 30:1175–1182 (2009).
7.
Boudailliez B, Morichon-Delvallez N, Goldfarb A, Pautard JC, Lenaerts C, Piussan C: Solitary upper incisor, hypopituitarism and monosomy 18p chromosome aberration. J Genet Hum 31:39–42 (1983).
8.
Chen CP, Chern SR, Du SH, Wang W: Molecular diagnosis of a novel heterozygous 268C→T (R90C) mutation in TGIF gene in a fetus with holoprosencephaly and premaxillary agenesis. Prenat Diagn 22:5–7 (2002).
9.
Chen M, Kuo SJ, Liu CS, Chen WL, Ko TM, et al: A novel heterozygous missense mutation 377T>C (V126A) of TGIF gene in a family segregated with holoprosencephaly and moyamoya disease. Prenat Diagn 26:226–230 (2006).
10.
Dolan LM, Willson K, Wilson WG: 18p– syndrome with a single central maxillary incisor. J Med Genet 18:396–398 (1981).
11.
Dubourg C, Bendavid C, Pasquier L, Henry C, Odent S, David V: Holoprosencephaly. Orphanet J Rare Dis 2:8–21 (2007).
12.
El-Jaick KB, Powers SE, Bartholin L, Myers KR, Hahn J, et al: Functional analysis of mutations in TGIF associated with holoprosencephaly. Mol Genet Metab 90:97–111 (2007).
13.
Faust J, Habedank M, Nieuwenhuijsen C: The 18p– syndrome. Report of four cases. Eur J Pediatr 123:59–66 (1976).
14.
Gripp KW, Wotton D, Edwards MC, Roessler E, Ades L, et al: Mutations in TGIF cause holoprosencephaly and link NODAL signaling to human neural axis development. Nat Genet 25:205–208 (2000).
15.
Hahn JS, Barnes PD: Neuroimaging advances in holoprosencephaly: Refining the spectrum of the midline malformation. Am J Med Genet C Semin Med Genet 154C:120–132 (2010).
16.
Hahn JS, Barkovich AJ, Stashinko EE, Kinsman SL, Delgado MR, Clegg NJ: Factor analysis of neuroanatomical and clinical characteristics of holoprosencephaly. Brain Dev 28:413–419 (2006).
17.
Hahn JS, Barnes PD, Clegg NJ, Stashinko EE: Septopreoptic holoprosencephaly: a mild subtype associated with midline craniofacial anomalies. AJNR Am J Neuroradiol 31:1596–1601 (2010).
18.
Hayhurst M, McConnell SK: Mouse models of holoprosencephaly. Curr Opin Neurol 16:135–141 (2003).
19.
Jin JZ, Gu S, McKinney P, Ding J: Expression and functional analysis of Tgif during mouse midline development. Dev Dyn 235:547–553 (2006).
20.
Kauvar EF, Hu P, Pineda-Alvarez DE, Solomon BD, Dutra A, et al: Minimal evidence for a direct involvement of twisted gastrulation homolog 1 (TWSG1) gene in human holoprosencephaly. Mol Genet Metab 102:470–480 (2011).
21.
Knepper JL, James AC, Ming JE: TGIF, a gene associated with human brain defects, regulates neuronal development. Dev Dyn 235:1482–1490 (2006).
22.
Küchle M, Kraus J, Rummelt C, Naumann GO: Synophthalmia and holoprosencephaly in chromosome 18p deletion defect. Arch Ophthalmol 109:136–137 (1991).
23.
Lacbawan F, Solomon BD, Roessler E, El-Jaick K, Domené S, et al: Clinical spectrum of SIX3-associated mutations in holoprosencephaly: correlation between genotype, phenotype, and function. J Med Genet 46:389–398 (2009).
24.
Lazaro L, Dubourg C, Pasquier L, Le Duff F, Blayau M, et al: Phenotypic and molecular variability of the holoprosencephalic spectrum. Am J Med Genet A 129A:21–24 (2004).
25.
Leoncini E, Baranello G, Orioli IM, Annerén G, Bakker M, et al: Frequency of holoprosencephaly in the International Clearinghouse Birth Defect Surveillance Systems: searching for population variations. Birth Defects Res A Clin Mol Teratol 82:585–591 (2008).
26.
Levey EB, Stashinko E, Clegg NJ, Delgado MR: Management of children with holoprosencephaly. Am J Med Genet C Semin Med Genet 154C:183–190 (2010).
27.
Maden M: Retinoid signaling in the development of the central nervous system. Nat Rev Neurosci 3:843–853 (2003).
28.
Matsunaga E, Shiota K: Holoprosencephaly in human embryos: epidemiologic studies in 150 cases. Teratology 16:261–272 (1977).
29.
Melhuish TA, Wotton D: The interaction of the carboxyl terminus-binding protein with the Smad corepressor TGIF is disrupted by a holoprosencephaly mutation in TGIF. J Biol Chem 275:39762–39766 (2000).
30.
Ming JE, Muenke M: Multiple hits during early embryonic development: digenic diseases and holoprosencephaly. Am J Hum Genet 71:1017–1032 (2002).
31.
Moog U, De Die-Smulders CE, Schrander-Stumpel CT, Engelen JJ, Hamers AJ, et al: Holoprosencephaly: the Maastricht experience. Genet Couns 12:287–298 (2001).
32.
Morales-Peralta E, Lantigua A: Deletion 18p associated with a single maxillary incisor: a case study. Rev Brasil Genet 17:341–343 (1994).
33.
Mukherjee K, Bürglin: Comprehensive analysis of animal TALE homeobox genes: new conserved motifs and cases of accelerated evolution. J Mol Evol 65:137–153 (2007).
34.
Münke M: Clinical, cytogenetic and molecular approaches to the genetic heterogeneity of holoprosencephaly. Am J Med Genet 34:237–245 (1989).
35.
Münke M, Page DC, Brown LG, Armson BA, Zackai EH, et al: Molecular detection of a Yp/18 translocation in a 45,X holoprosencephalic male. Hum Genet 80:219–223 (1988).
36.
Nanni L, Ming JE, Bocian M, Steinhaus K, Bianchi DW, et al: The mutational spectrum of the sonic hedgehog gene in holoprosencephaly: SHH mutations cause a significant proportion of autosomal dominant holoprosencephaly. Hum Mol Genet 8:2479–2488 (1999).
37.
Nosaka T, Morita S, Kitamura H, Nakajima H, Shibata F, et al: Mammalian twisted gastrulation is essential for skeleto-lymphogenesis. Mol Cell Biol 23:2969–2980 (2003).
38.
Orioli IM, Castilla EE: Clinical epidemiologic study of holoprosencephaly in South America. Am J Med Genet A 143A:3088–3099 (2007).
39.
Overhauser J, Mitchell HF, Zackai EH, Tick DB, Rojas K, Muenke M: Physical mapping of the holoprosencephaly critical region in 18p11.3. Am J Hum Genet 57:1080–1085 (1995).
40.
Petryk A, Anderson RM, Jarcho MP, Leaf I, Carlson CS, et al: The mammalian twisted gastrulation gene functions in foregut and craniofacial development. Dev Biol 267:374–386 (2004).
41.
Pineda-Alvarez DE, Dubourg C, David V, Roessler E, Muenke M: Current recommendations for the molecular evaluation of newly diagnosed holoprosencephaly patients. Am J Med Genet C Semin Med Genet 154C:93–101 (2010).
42.
Plawner LL, Delgado MR, Miller VS, Levey EB, Kinsman SL, et al: Neuroanatomy of holoprosencephaly as a predictor of function: beyond the face predicting the brain. Neurology 50:1058–1066 (2002).
43.
Portnoï MF, Gruchy N, Marlin S, Finkel L, Denoyelle F, et al: Midline defects in deletion 18p syndrome: clinical and molecular characterization of three patients. Clin Dysmorphol 16:247–252 (2007).
44.
Powers SE, Taniguchi K, Yen W, Melhuish TA, Shen J, et al: Tgif1 and Tgif2 regulate Nodal signaling and are required for gastrulation. Development 137:249–259 (2010).
45.
Richieri-Costa A, Ribeiro LA: Variable phenotypic manifestations of a K44N mutation in the TGIF gene. Brain Dev 30:203–205 (2008).
46.
Roessler E, Muenke M: Holoprosencephaly: a paradigm for the complex genetics of brain development. J Inherit Metab Dis 21:481–497 (1998).
47.
Roessler E, Muenke M: The molecular genetics of holoprosencephaly. Am J Med Genet C Semin Med Genet 154C:52–61 (2010).
48.
Roessler E, Belloni E, Gaudenz K, Jay P, Berta P, et al: Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. Nat Genet 14:357–360 (1996).
49.
Roessler E, El-Jaick KB, Dubourg C, Vélez JI, Solomon BD, et al: The mutational spectrum of holoprosencephaly-associated changes within the SHH gene in humans predicts loss-of-function through either key structural alterations of the ligand or its altered synthesis. Hum Mutat 10:E921–E935 (2009).
50.
Rosenfeld JA, Ballif BC, Martin DM, Aylsworth AS, Bejjani BA, et al: Clinical characterization of individuals with deletions of genes in holoprosencephaly pathways by aCGH refines the phenotypic spectrum of HPE. Hum Genet 127:421–440 (2010).
51.
Schachter KA, Krauss RS: Murine models of holoprosencephaly. Curr Top Dev Biol 84:139–170 (2008).
52.
Sepulveda W: Monosomy 18p presenting with holoprosencephaly and increased nuchal translucency in the first trimester: report of 2 cases. J Ultrasound Med 28:1077–1080 (2009).
53.
Solomon BD, Lacbawan F, Jain M, Domené S, Roessler E, et al: A novel SIX3 mutation segregates with holoprosencephaly in a large family. Am J Med Genet A 149A:919–925 (2009a).
54.
Solomon BD, Lacbawan F, Mercier S, Clegg NJ, Delgado MR, et al: Mutations in ZIC2 in human holoprosencephaly: description of a novel ZIC2-specific phenotype and comprehensive analysis of 157 individuals. J Med Genet 47:513–524 (2009b).
55.
Solomon BD, Mercier S, Vélez JI, Pineda-Alvarez DE, Wyllie A, et al: Analysis of genotype-phenotype correlations in human holoprosencephaly. Am J Med Genet C Semin Med Genet 154C:133–141 (2010).
56.
Stashinko EE, Clegg NJ, Kammann HA, Sweet VT, Delgado MR, et al: A retrospective study of perinatal risk factors of 104 living children with holoprosencephaly. Am J Med Genet A 128A:114–119 (2004).
57.
Sulik KK, Dehart DB, Rogers JM, Chernoff N: Teratogenicity of low doses of all-trans retinoic acid in presomite mouse embryos. Teratology 51:398–403 (1995).
58.
Turleau: Monosomy 18p. Orphanet J Rare Dis 3:4–8 (2008).
59.
Wotton D, Lo RS, Lee S, Massague JA: Smad transcriptional corepressor. Cell 97:29–39 (1999a).
60.
Wotton D, Lo RS, Swaby LA, Massagué J: Multiple modes of repression by the Smad transcriptional corepressor TGIF. J Biol Chem 274:37105–37110 (1999b).
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.